7. Cyclosporine

Cyclosporine nephrotoxicity.

After more than 20 years of cyclosporine use its nephrotoxicity remains a significant clinical problem. Cyclosporine-induced renal injury has been described in solid organs recipients and in patients treated for autoimmune diseases. It is manifested in 2 distinct and well characterized forms, acute nephrotoxicity and chronic nephrotoxicity. This communication reviews the current literature anal...

Increased cyclosporine concentrations in the absence of cyclosporine administration.

A 9-year-old girl was admitted to our hospital with juvenile metachromatic leukodystrophy (arylsulfatase A deficiency). Symptoms of this lysosomal storage disease, such as decreased school performance and compromised motor skills, had started 1 year earlier. She underwent bone marrow transplantation from a matched unrelated donor after receiving conditioning with fludarabine, treosulfan, and th...

Canine liver transplantation under Nva2-cyclosporine versus cyclosporine.

The immunosuppressive qualities and other features of a new cyclosporine (CsA) analogue, Nva2-cyclosporine (Nva2-CsA) were examined using canine orthotopic liver allografts. The mean survival time was 11.8 +/- 9.6 (SD) days in dogs without treatment, 60.8 +/- 4.4 days with Nva2-CsA and 65.1 +/- 33.0 days with CsA. Functional abnormalities indicating toxic side effects were not noted either with...

Comparative pharmacokinetics of cyclosporine and NVa2-cyclosporine in dogs.

Cyclosporine and multiple sclerosis.

I read with interest the paper by The Multiple Sclerosis Study Group reporting that cyclosporine delayed the progression of multiple sclerosis [l]. As stated in the introduction, the rationale for undertaking the study was partly based on the ability of cyclosporine to suppress the development of experimental allergic encephalomyelitis (EAE), a T-cell-mediated autoimmune disease that serves as ...